Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature

The three different botulinum toxin type A (BoNT/A) preparations being licensed in Europe and the U.S. differ in protein content, which seems to be a major factor influencing the antigenicity of BoNT/A. In the present study, several arguments out of our research pool were collected to demonstrate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Samadzadeh, Sara, Ürer, Beyza, Brauns, Raphaela, Rosenthal, Dietmar, Lee, John-Ih, Albrecht, Philipp, Hefter, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472361/
https://www.ncbi.nlm.nih.gov/pubmed/32759685
http://dx.doi.org/10.3390/toxins12080499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472361/
https://www.ncbi.nlm.nih.gov/pubmed/32759685
http://dx.doi.org/10.3390/toxins12080499

Ejemplares similares